(Bloomberg) — The leading group of U.S. cancer doctors created a scoring system for oncology drugs, awarding a zero for overall benefit to the $9,200-a-month regimen featuring Eli Lilly & Co.'s Alimta.
The formula ranges from 0 to 100 points and was published Monday in the Journal of Clinical Oncology. It aims to simplify the complex statistics behind cancer medicines into a single "net health benefit" score that weighs a drug's ability to extend life or delay progression against potential toxic side effects.
The ultimate goal is to assess many drugs and put the data into a user-friendly mobile software application that patients and doctors can use at the bedside, said Richard Schilsky, chief medical officer for the American Society of Clinical Oncology, which convened a task force to assess value.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
